Last reviewed · How we verify

Insuline Glulisine

Sanofi · Phase 3 active Small molecule

Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.

Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameInsuline Glulisine
SponsorSanofi
Drug classRapid-acting insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Insulin glulisine is a recombinant human insulin analog engineered with amino acid substitutions (lysine at position B3 and glutamic acid at position B29) to accelerate absorption and onset of action compared to regular human insulin. It mimics the body's natural rapid insulin secretion in response to meals, binding to insulin receptors and facilitating cellular glucose uptake while suppressing hepatic glucose production and lipolysis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: